Opening Plenary at AACR 2018; ©AACR/Todd Buchanan

The AACR Annual Meeting 2018 took place April 14-18 in Chicago, Illinois.

Radioimmunoconjugate shows activity in NHL

Print Friendly, PDF & Email


Mantle cell lymphoma
The radioimmunoconjugate 177Lu-NNV003 has demonstrated activity against non-Hodgkin lymphomas (NHLs). Experiments showed that 177Lu-NNV003 can inhibit proliferation in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL) cell lines. 177Lu-NNV003 also exhibited an antitumor effect and prolonged survival in mouse models of MCL, DLBCL, and CLL.... [Read Article]
Print Friendly, PDF & Email

CDK inhibitor synergizes with venetoclax in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Researchers have reported “strong synergy” between the CDK2/9 inhibitor CYC065 and the Bcl-2 inhibitor venetoclax in chronic lymphocytic leukemia (CLL). Experiments indicated that CYC065 and venetoclax target parallel mechanisms that promote survival in CLL cells, working together to induce apoptosis. The drugs demonstrated synergy even in CLL samples that are... [Read Article]
Print Friendly, PDF & Email

Exercise linked to risk of death in cancer patients

Print Friendly, PDF & Email


Woman exercising
Photo by Petr Kratochvil
Researchers have identified a link between habitual physical activity (PA) and mortality among cancer patients. Engaging in regular PA, both pre- and post-diagnosis, was associated with a significantly lower risk of death for the entire population studied and for patients with 8 specific types of cancer. However,... [Read Article]
Print Friendly, PDF & Email

BET inhibitor has lasting effects in AML, MM

Print Friendly, PDF & Email


Lab mice
Photo by Aaron Logan
A BET inhibitor can have potent and long-lasting effects against leukemia and multiple myeloma (MM), according to researchers. The inhibitor, TG-1601 (or CK-103), exhibited cytotoxicity in MM and leukemia cell lines but did not affect the growth of normal cell lines. TG-1601 also reduced tumor volume in mouse... [Read Article]
Print Friendly, PDF & Email

Inhibitor outperforms rivals in leukemia, lymphoma

Print Friendly, PDF & Email


Researchers in the lab
Photo by Rhoda Baer
Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]
Print Friendly, PDF & Email

Team uses iPSCs to create ‘universal’ CAR T cells

Print Friendly, PDF & Email


Induced pluripotent stem cells
Image by James Thomson
Researchers have used induced pluripotent stem cells (iPSCs) to create a “universal” chimeric antigen receptor (CAR) T-cell therapy known as FT819. The team says FT819 has the potential to be mass-produced, stored, and made readily available for cancer patients. In in vitro experiments, FT819 demonstrated... [Read Article]
Print Friendly, PDF & Email

Antibody has ‘potent’ effects against AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML), according to researchers. APVO436 binds CD123 and CD3 to redirect T-cell cytotoxicity against CD123-expressing tumor cells. Researchers found that APVO436 induced T-cell cytotoxicity in AML cells in... [Read Article]
Print Friendly, PDF & Email